Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Sofinno­va In­vest­ments, one of the longest-stand­ing biotech in­vest­ment firms, has pen­ciled in plans for a new $550 mil­lion fund, End­points News has learned.

The Men­lo …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER